BioForce targets NIH (National Institutes of Health) grant at NanoArray technology:
This article was originally published in Clinica
BioForce Nanosciences will use a $500,000 grant from the US National Institutes of Health to develop its Nanoarrayer molecular deposition tool, a technology for creating miniaturised biological tests. The technology, which places thousands of molecules at defined locations on a single microarray spot, allows for the development of a broad spectrum of ultra-sensitive, ultra-miniaturised biological tests, such as blood screens and the detection of pathogenic material, says the Ames, Iowa firm.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.